Tomasoni D, Bai F, Castoldi R, et al. Anxiety and depression symptoms after virological clearance of COVID-19: a cross-sectional study in Milan, Italy [published online ahead of print, 2020 Aug 25]. J Med Virol. 2020;10.1002/jmv.26459. doi:10.1002/jmv.26459

Prevalence of anxiety/depression was investigated in 105 COVID-19 patients at 1-3 months from virological clearance by Hospital Anxiety and Depression Scale (HADS-A/D). 30% of patients displayed pathological HADS-A/D, 52.4% showed persistent symptoms. Pathological HADS-A/D patients more commonly reported symptom persistence, even after adjustment for age, gender, disease severity. Psychological assessments should be encouraged in COVID-19 patients’ follow-up. This article is protected by copyright.